Specific Biotechnologies

  • Antibody-drug conjugate technologies
  • Biomarker-driven therapies
  • Biosimilars
  • CAR-T cell therapy
  • Checkpoint inhibitors
  • Colony stimulating factors
  • Digital inhalers
  • Enzyme-replacement therapies
  • Follow-on biologics
  • Immune modulators
  • Implantable contraceptive devices
  • Monoclonal antibodies
  • Respiratory delivery systems
  • Sustained-release injectable prodrugs
  • Targeted therapies
  • Thermosensitive polymers
  • Vaccine technology
  • Viscosupplements and cartilage repair

Aventine has prepared dossiers and economic models for a wide variety of novel biotechnology products across many therapeutic areas. These products have included cutting-edge molecules and delivery systems in areas with substantial previously-unmet medical need. Our experience in biotechnologies is not limited to the list shown above; rather, the items listed illustrate the range of products for which we have provided writing services – encompassing recombinant technologies, novel drug-antibody conjugates, devices, and unique delivery systems.